Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03126981 · ClinicalTrials.gov registry record · NA
Effects of Almonds on Insulin Sensitivity in Prediabetes
A NA study, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
NCT03126981: Completed NA study, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
NCT03126981 is a NA study that has completed, run by Midwest Center for Metabolic and Cardiovascular Research. The registered enrollment target is 54 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03126981, a NA study, has completed, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate the effects of consuming 1.5 oz almonds twice daily on insulin sensitivity and markers of cardiometabolic health in men and women with prediabetes.
Primary Outcome
SI from a short (50-min) intravenous glucose tolerance test (IVGTT) at baseline(day 0) and end of two treatment periods (day 43 of both treatment periods)
Interventions
- OTHER 1.5 oz of whole, natural almonds
- OTHER Low-fat, high refined starches/sugars
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-04-20 |
| Est. Completion | 2018-09-26 |
| Phase | NA |
What the finished NCT03126981 record still lists
NCT03126981 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which 1.5 oz of whole, natural almonds is the first listed.
NCT03126981 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03126981 about?
NCT03126981 is a clinical study titled "Effects of Almonds on Insulin Sensitivity in Prediabetes". The goal of this clinical trial is to evaluate the effects of consuming 1.5 oz almonds twice daily on insulin sensitivity and markers of cardiometabolic health in men and women with prediabetes.
What is the current status of trial NCT03126981?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2017-04-20. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT03126981?
The interventions under investigation include: 1.5 oz of whole, natural almonds (OTHER), Low-fat, high refined starches/sugars (OTHER).
Who is sponsoring clinical trial NCT03126981?
This trial is sponsored by Midwest Center for Metabolic and Cardiovascular Research, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03126981's enrollment target sits among peer trials
54 1268th of 2000 higher than 730 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI